Dorsal Root Ganglion Stimulation.

The recent development and Food and Drug Administration approval in 2016 of dorsal root ganglion stimulation is a relatively new and novel form of target neuromodulation that promises improved outcomes compared with the current standard of care. Current literature is limited and dependent on industry evaluation. Future independent investigation will help clarify existing data and refine techniques to improve safety, effectiveness, and expand application.